TheSinopharm WIBP COVID-19 vaccine, also known asWIBP-CorV,[2][3] is one of twoinactivated virusCOVID-19 vaccines developed bySinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group).[4] The other inactivated virus COVID-19 vaccine developed by Sinopharm is theBIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.
In May 2021, peer-reviewed results published inJAMA of Phase III trials inUnited Arab Emirates andBahrain showed that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). 12,743 people received the vaccine and 12,737 people received the placebo in these trials.[4]
In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed bySinopharm's Beijing Institute of Biological Products (BIBP)[9] and the Wuhan Institute of Biological Products (WIBP).[10] Both vaccines are chemically-inactivated whole virus vaccines forCOVID-19.[citation needed]
On August 13, 2020, theWuhan Institute of Biological Products published interim results of its Phase I (96 adults) and Phase II (224 adults) clinical studies. The report noted the vaccine had a low rate of adverse reactions and demonstratedimmunogenicity, but longer-term assessment of safety and efficacy would require Phase III trials.[10]
In March 2021,Cayetano Heredia University running the BIBP and WIBP trials in Peru announced they were seeking to suspend and unblind participants in the WIBP trials for lower efficacy and offer the participants the BIBP vaccine instead, which was showing efficacy.[11]
On February 25, 2021, China approved the vaccine for general use.[12]
According toThe New York Times, the vaccine is only approved for limited use inUnited Arab Emirates.[13] On August 19, 2021, the Philippines approved the vaccine for emergency use authorization.[14]
.svg)
COVID-19 portal
